Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Teva appears to be a company with stable revenue and a notable liquidity cushion, but with a rich valuation and weak profitability relative to the industry. A P/E of 57.39 and P/B of 5.95 are significantly above the sector median, which means the market has already priced in a substantial portion of the expected improvements. P/FCF of 32.88 also looks elevated, while P/S is only slightly below the industry median, so by valuation multiples the stock does not look cheap. At the same time, leverage remains high: debt/equity of 1.56 is well above the industry level, and long-term debt of $14.0 billion limits balance sheet flexibility. Liquidity is also not ideal: a current ratio of 1.04 and quick ratio of 0.67 indicate a narrow cushion for short-term obligations. On the other hand, cash on hand of $3.66 billion and shareholders’ equity of $7.76 billion support financial stability better than many weaker issuers. Revenue of $4.14 billion and gross profit of $2.15 billion confirm the scale of the business, and the gross margin of 52.46% remains a strength. However, operating and net profitability have deteriorated noticeably: operating margin is 8.77%, net profit margin is 4.08%, while TTM net income and operating income are shown as zero, which looks worse than the recent quarterly figures. ROE, ROA, and ROI are below the industry median, indicating insufficiently efficient use of capital and assets. EBITDA also looks weaker in the latest TTM snapshot, which reduces the quality of current cash flow. The dividend yield of 0.58% is too low to be a meaningful support factor for the valuation. Overall, the fundamentals point to a mature business with acceptable revenue and margins, but without convincing efficiency improvement and with a significant debt burden. Therefore, the target forecast looks slightly overstated and requires a moderate conservative downward adjustment.

Teva Pharmaceutical Industries Limited

Сильный индекс, значительно вырос. Быки резко укрепили уверенность в своих позициях.

Strong index, significantly up. Bulls sharply strengthened confidence in their positions.

Слабый индекс, значительно вырос. Рынок не поддерживает быков.

Weak index, significantly up. The market does not support the bulls.

Сильный индекс, значительно упал. Отток средств из лонгов увеличился и находится на высоком уровне.

Strong index, significantly down. The outflow of funds from longs has increased and is at a high level.

Teva has strong revenue and gross margin, but its high valuation, weak profitability, and significant debt limit revaluation potential.

FDA Drug Approvals In September 2026

Key Points
Forecasts call for Teva's branded drug portfolio to bring it $3.7 billion in revenue next year.
At the same time, as it pivots toward high-margin drug products, Teva continues to reduce debt and improve its credit rating.
With management guiding toward a branded pivot that could eventually generate over $10 billion annually, there may be far more runway for Teva's turnaround rally.
Teva Pharmaceuticals (NYSE: TEVA) recently hit a new 52-week high of $40.79 per share and has surged 110% in the last year. It's the drugmaker's turnaround, fueled by a pivot from generic to branded products, driving this mega rally among pharmaceutical stocks.
To some, it still doesn't make sense that Teva surged so far, so fast, given that the company has yet to see a big jump in revenue or earnings. However, a closer look at three company metrics makes it clear why investors continue to bid shares higher.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
$3.7 billion: forecasted sales for Teva's new drugs
Teva's "Innovative Portfolio" of branded drugs so far consists of three products: Austedo, Uzedy, and Ajovy. During Q2 2026, these three products combined to generate just over $1 billion in revenue. For the full year 2026, management anticipates sales for the three totaling $3.7 billion.
This is only around 22% of Teva's estimated 2026 sales. However, management guides for further "Innovative Portfolio" growth, to the point where it has a significant impact on company-wide gross margins.
$12.9 billion: Teva's outstanding debt position
As of June 30, 2026, Teva's net outstanding debt was $12.9 billion. Compare that to the end of 2022, when Teva's net debt totaled $18.4 billion.
The company also recently received a credit rating upgrade, which raised its long-term issuer rating from BB- to BBB-. With its debt moving from "junk" to investment-grade status, Teva is now well positioned to refinance its remaining debt at lower interest rates.
$10 billion: the potential for Teva's drug pipeline
Between the company's existing pipeline and the candidates gained through its recent acquisition of Emalex Biosciences, the company anticipates peak annual sales of at least $10 billion from its late-stage pipeline portfolio.
Just between 2026 and 2027, analysts expect the company's earnings to grow 40.7%, from $2.16 to $3.04 per share. Considering the prospect of even greater earnings growth in subsequent years, shares arguably appear cheap at just 12.9 times next year's forecast earnings.
Should you buy stock in Teva Pharmaceutical Industries right now?
Before you buy stock in Teva Pharmaceutical Industries, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teva Pharmaceutical Industries wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $383,680!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,382,954!*
Now, it’s worth noting Stock Advisor’s total average return is 937% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 29, 2026.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA as a biosimilar to Xgeva (denosumab).
The FDA approved DEGEVMA based on analytical and clinical data demonstrating efficacy, safety, and immunogenicity comparable to the reference product, Xgeva.
DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, the treatment of adults and skeletally mature adolescents with giant cell tumour of bone, and the treatment of hypercalcemia of malignancy.
The comprehensive data package submitted to the FDA showed that DEGEVMA had no clinically meaningful differences from the reference product in terms of safety, purity, and potency, the company said.
The FDA approval of DEGEVMA, along with PONLIMSI (denosumab-adet), approved in March 2026, establishes a comprehensive U.S. denosumab biosimilar portfolio covering the indications of Xgeva and Prolia, respectively. DEGEVMA is also currently approved in the European Union (EU).
Teva expects to launch DEGEVMA and PONLIMSI in the U.S. in the coming months as part of its biosimilar commercialisation strategy.
TEVA has traded between $18.83 and $40.79 over the last year. The stock closed Monday's trade at $38.88, down 0.79%.
In the after-hours market, TEVA is up 0.31% at $39.00.
For more such biotech news, visit www,rttnews.com

Teva Pharma Secures FDA Nod For DEGEVMA, A Biosimilar To Xgeva

(RTTNews) - Teva Pharmaceutical Industries (TEVA) on Friday reported new real-world data showing that UZEDY helped patients with schizophrenia remain on treatment longer while reducing emergency room visits, hospitalizations, and overall healthcare costs compared with certain other long-acting injectable therapies. The findings were presented at Psych Congress 2026, in New Orleans.
Schizophrenia is a chronic mental health disorder that affects how people think, feel, and behave. Relapses often lead to psychiatric emergencies and hospitalizations, making long-term treatment adherence a key goal of care.
UZEDY is an extended-release injectable form of risperidone approved for the treatment of schizophrenia in adults and for the maintenance treatment of bipolar I disorder. The therapy is administered as a subcutaneous injection and is available in one-month and two-month dosing intervals.
In one analysis involving 1,166 matched schizophrenia patients, fewer patients treated with once-monthly UZEDY visited the emergency department compared with those receiving once-monthly paliperidone palmitate (22.0% versus 27.8%). UZEDY patients also experienced a 40% lower rate of all-cause emergency department visits and lower monthly healthcare costs, resulting in estimated savings of more than $1,000 per patient per month.
A separate analysis compared UZEDY with other long-acting injectable antipsychotics, including risperidone microspheres, aripiprazole once-monthly and haloperidol decanoate. Patients receiving UZEDY showed higher treatment adherence and were less likely to discontinue therapy, particularly when compared with risperidone microspheres. The study also found lower rates of emergency department visits and hospitalizations among UZEDY-treated patients.
Teva also presented data in bipolar I disorder. In a retrospective review of 358 matched patients, those switched from oral antipsychotics to UZEDY experienced lower treatment failure rates than patients switched to another oral antipsychotic (47% versus 63%). Patients receiving UZEDY were also more likely to remain on treatment without bipolar-related hospitalizations, emergency department visits, or discontinuations due to inadequate effectiveness.
According to Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva, the findings demonstrate the potential impact of helping patients stay on treatment and avoid psychiatric emergencies.
The company said the results add to the growing body of real-world evidence supporting UZEDY's use in severe mental illnesses, including schizophrenia and bipolar I disorder.
TEVA has traded between $18.21 and $39.70 over the past year. The stock closed Friday's trading (September 18, 2026) at $38.98, down 0.54%. During the after-hours trading session, the stock is at $38.66, down 0.82%.

Teva's UZEDY Linked To Fewer Emergency Visits And Lower Healthcare Costs In Real-World Study

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a generic drugs company, on Friday presented positive post-hoc data from the Phase 3 SOLARIS trial for TEV-'749 in treating schizophrenia. The results were presented at the Psych Congress in New Orleans, Louisiana.
Schizophrenia is a chronic, progressive, and debilitating mental disorder that affects a patient's thoughts and actions through delusions, hallucinations, and impaired cognition. Approximately 1% of the world's population will develop the disease at some point in their lives, with an estimated 2.2 million individuals affected in the U.S. alone. Long-term therapies may result in total or partial remission, yet over 80% of patients experience a relapse within the first five years of treatment.
Olanzapine was first approved by the U.S. Food and Drug Administration (FDA) for schizophrenia in 2009. Developed by Eli Lilly & Co and marketed as Zyprexa Relprevv, the drug is the most widely prescribed atypical antipsychotic for schizophrenia as a daily oral treatment. However, issues with adherence lead to a higher risk for instability and relapse, contributing to its limited use for a sustained effect.
TEV-'749 was designed as a once-monthly, subcutaneous long-acting injectable (LAI) formulation of olanzapine. The drug was developed using the SteadyTeq copolymer technology from Medincell facilitating a controlled, sustained release.
The Phase 3 SOLARIS trial was a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of TEV-'749. A total of 675 schizophrenia patients were enrolled, with the primary endpoint set at an improvement on the Positive and Negative Syndrome Scale (PANSS).
Among the dosed participants, 231 showed stabilization with a 4% relapse rate. Additionally, of the 183 patients who received TEV-'749 for six months or more, 39 achieved remissions.
The company also recorded possible success in switching patients on oral olanzapine to TEV-'749, with exposures remaining within normal oral therapeutic ranges. The safety profile of the drug was also found to be consistent across various dosing regimens.
The FDA has set a Prescription Drug User Fee Act (PDUFA) date for TEV-'749 in the fourth quarter of this year, and the European Medicines Agency (EMA) accepted a marketing authorization application (MAA) for the same in May 2026.
TEVA closed Friday at $39.98, down 0.54%.

Teva Presents Positive Post Hoc Data For TEV-'749 For Schizophrenia; FDA Decision In Q4 '26

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of LongActingImpact.com, a new educational resource for healthcare providers focused on the role of long-acting injectables (LAIs) in schizophrenia care.
The website is designed to support clinicians in treatment discussions and decision-making around LAIs, including their potential role in improving medication adherence and reducing relapse risk.
LongActingImpact.com provides information on how LAIs can help patients who struggle with daily medication adherence, support continuity of care during the transition from inpatient to outpatient settings and potentially improve treatment outcomes.
The resource also offers practical guidance for clinicians on discussing LAI treatment with patients, including identifying patient goals, building trust and maintaining ongoing dialogue.
According to an analysis cited by Teva, 67% of patients taking oral medications for schizophrenia were nonadherent or discontinued treatment altogether. Despite the availability of LAIs, Teva said these treatments remain underutilized due to perceived patient resistance and operational challenges.
Teva is positioning the new resource as part of its broader efforts in neuroscience to provide evidence-based information and support clinicians in schizophrenia care.
The company said approximately 2.2 million people in the U.S. are currently diagnosed with schizophrenia.
Next Steps
Teva's LongActingImpact.com is now available online to healthcare providers, offering educational resources and practical guidance on incorporating long-acting injectables into schizophrenia treatment discussions and care.
TEVA has traded between $18.21 and $39.49 over the past year. The stock closed Tuesday's trading at $39.25, up 1.37%. In pre-market trading the stock is at $39.47, up 0.66%.

Teva Launches LongActingImpact.com To Support Earlier Schizophrenia Care

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a biopharmaceutical company, announced on Monday the upcoming initiation of direct trade on the New York Stock Exchange (NYSE). The listing is expected to follow a transition from the company's American Depositary Shares (ADS) program. The company's ordinary shares will continue trading on the NYSE and the Tel Aviv Stock Exchange (TASE) under the ticker symbol 'TEVA'. Teva stated that the transition was a part of its planned Pivot to Growth strategy. CEO Richard Francis stated that the move would help 'broaden investor access', and 'drive sustainable growth'. The company is an emerging global supplier of generic medicines and biosimilars. Sales of its flagship products AJOVY, UZEVY, and AUSTEDO resulted in a 40% year-on-year revenue growth in 2025. Revenues in 2026 are estimated to reach $3.7 billion.
As of June 30, 2026, Teva held cash and cash equivalents of $3,655 million. TEVA closed Friday (11.09.2026) at $37.09, up 2.04%.
On Monday, shares of Teva closed at $38.72, up 4.39%. In the overnight trade, shares are down 2.32% at $37.82.

Teva Transitions To Direct Listing On NYSE

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an approximate $808.6 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 1,942,200,000 to 1,950,200,000). Among the largest underlying components of IEFA, in trading today Spotify Technology SA (Symbol: SPOT) is down about 2.1%, Sea Ltd (Symbol: SE) is up about 0.1%, and Teva Pharmaceutical Industries Ltd (Symbol: TEVA) is lower by about 0.1%. For a complete list of holdings, visit the IEFA Holdings page » The chart below shows the one year price performance of IEFA, versus its 200 day moving average:
Looking at the chart above, IEFA's low point in its 52 week range is $85.025 per share, with $101.44 as the 52 week high point — that compares with a last trade of $100.72. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Further IEFA Research:

IEFA, SPOT, SE, TEVA: ETF Inflow Alert

(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), a biopharmaceutical company, announced its intentions to issue senior notes through its special-purpose finance subsidiaries.
Teva Pharmaceutical Finance Netherlands II B.V. (Teva Finance II) intends to issue euro-denominated senior notes, while Teva Pharmaceutical Finance Netherlands III B.V. (Teva Finance III) and Teva Pharmaceutical Finance Netherlands IV B.V. (Teva Finance IV) intend to issue U.S. dollar-denominated senior notes. The offering is subject to market conditions.
The notes will be unsecured senior obligations of the issuing subsidiaries and will be unconditionally guaranteed on a senior basis by Teva.
Teva did not disclose the expected net proceeds from the offering. The company expects to use the net proceeds, together with cash on hand, to fund the redemption of certain outstanding notes, pay related fees and expenses, and for general corporate purposes, including debt repayment, through tender offers or earlier redemption.
The planned redemptions include all outstanding 6.750% senior notes due 2028, as well as the 7.875% and 7.375% sustainability-linked senior notes due 2029.
Additionally, Teva intends to redeem up to $450 million of 4.750% sustainability-linked senior notes due 2027, and up to €1.25 billions of 4.375% sustainability-linked senior notes due 2030.
The conditional redemptions are expected to depend on completion of the notes offering, while the offering itself is not conditioned on the redemptions. Teva may also modify the redemption amounts or redeem additional outstanding notes at its discretion.
As of June 30, 2026, cash and cash equivalents amounted to $3,655 million.
Teva shares have traded between $18.21 and $38.37 over the last year.
TEVA closed Friday's (04.09.2026) trade at $36.36, down 0.71%. In the after-hours trading on Friday, shares were up 2.28% at $37.19.

Teva Launches Senior Notes Offering To Refinance Existing Debt

The NASDAQ 100 After Hours Indicator is down -45.18 to 29,498.97. The total After hours volume is currently 112,199,562 shares traded.
The following are the most active stocks for the after hours session:
NIO Inc. (NIO) is +0.0015 at $3.80, with 7,386,156 shares traded. NIO's current last sale is 59.4% of the target price of $6.4.
Intel Corporation (INTC) is -0.19 at $95.61, with 4,907,016 shares traded. INTC's current last sale is 86.14% of the target price of $111.
Teva Pharmaceutical Industries Limited (TEVA) is unchanged at $36.36, with 4,896,424 shares traded. As reported by Zacks, the current mean recommendation for TEVA is in the "buy range".
Amazon.com, Inc. (AMZN) is -0.4853 at $258.02, with 3,419,005 shares traded. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Ford Motor Company (F) is -0.03 at $14.59, with 3,337,380 shares traded. F's current last sale is 97.27% of the target price of $15.
NVIDIA Corporation (NVDA) is -0.5 at $229.86, with 3,252,616 shares traded. Over the last four weeks they have had 10 up revisions for the earnings forecast, for the fiscal quarter ending Oct 2026. The consensus EPS forecast is $2.47. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
ExxonMobil Holdings Corporation (XOM) is unchanged at $159.47, with 3,141,002 shares traded. XOM's current last sale is 93.81% of the target price of $170.
Coca-Cola Company (The) (KO) is +0.07 at $88.14, with 3,027,325 shares traded. As reported by Zacks, the current mean recommendation for KO is in the "buy range".
CNH Industrial N.V. (CNH) is -0.01 at $14.39, with 2,705,790 shares traded., following a 52-week high recorded in today's regular session.
Arbutus Biopharma Corporation (ABUS) is +0.01 at $5.16, with 2,680,748 shares traded. As reported in the last short interest update the days to cover for ABUS is 15.101523; this calculation is based on the average trading volume of the stock.
Meta Platforms, Inc. (META) is -1.3124 at $615.46, with 2,550,356 shares traded. As reported by Zacks, the current mean recommendation for META is in the "buy range".
Super Micro Computer, Inc. (SMCI) is -0.0697 at $39.52, with 1,937,572 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2026. The consensus EPS forecast is $0.95. SMCI's current last sale is 94.1% of the target price of $42.